Skip to main content

Table 8 Base case results for patients without cirrhosis

From: Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US

Genotype Treatment Duration (weeks) Cost ($) Effectiveness (QALYs) ICER compared to benchmark ($/QALY) Adjacent ICER ($/QALY)
1 Viekira Pak + Ribavirin 12 97,380 19.9659 dominant  
Harvoni 12 106,830 19.9618 dominant dominated
Telaprevir + Peginterferon + Ribavirin for first 12 weeks, followed by additional 12 or 36 weeks of Peginterferon + Ribavirin 12 + 12 or 36 108,820 18.3364 benchmark dominated
Sofosbuvir + Peginterferon + Ribavirin (Treatment-naïve) 12 111,790 19.568 2,412 dominated
Olysio + Sovaldi 12 165,220 19.9356 35,268 dominated
2 Peginterferon + Ribavirin (Treatment-naïve) 24 45,560 18.7853 benchmark  
Initial: Peginterferon + Ribavirin; Follow-up: Sofosbuvir + Ribavirin for non-responders and relapsers. 24 + 12 50,340 19.9145 4,233 4,233
24 + 16 54,030 19.9975 6,987 44,457
Sofosbuvir + Ribavirin (Treatment-naïve) 12 99,540 20.0227 43,624 1,805,952
3 Peginterferon + Ribavirin (Treatment-naïve) 24 52,810 18.2828 benchmark  
Initial: Peginterferon + Ribavirin; Follow-up: Sofosbuvir + Ribavirin for non-responders and relapsers. 24 + 12 69,390 18.9351 25,418 25,418
24 + 16 70,220 19.4892 14,431 1,498
Sofosbuvir + Ribavirin (Treatment-naïve) 24 187,880 19.8033 88,833 374,594